SlideShare una empresa de Scribd logo
1 de 15
Descargar para leer sin conexión
Future Horizons in the Japanese Cancer Diagnostics Market:
Supplier Shares and Sales Forecasts for 40 Tumor Markers by
Market Segment
Report Details:
Published:August 2012
No. of Pages: 590
Price: Single User License – US$6700




Highlights
•Comprehensive 590-page analysis of the Japanese tumor marker testing market.
•Major issues pertaining to the Japanese laboratory practice, as well as key economic, regulatory,
 demographic, social and technological trends with significant market impact during the next ten
 years.
•Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung,
 colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver,
 ovarian, testicular, oral, skin and others.
•Ten-year test volume and sales forecasts over for 40 tumor marker performed in Japanese
 hospitals, commercial laboratories and physician offices.
•Placements and installed base of automated and semi-automated analyzers used for tumor
 marker testing.
•Current instrumentation technologies and feature comparison of leading analyzers.
•Sales and market shares of leading suppliers.
•Emerging diagnostic technologies and their potential market applications.
•Product development opportunities.
•Profiles of current and emerging suppliers, including their sales, market shares, product
 portfolios, marketing tactics, technological know-how, new products in R&D, collaborative
 arrangements and business strategies.
•Business opportunities and strategic recommendations for suppliers.

Contains: 590 pages and 95 tables.


Get your copy of this report @
http://www.reportsnreports.com/reports/187741-future-horizons-in-the-japanese-cancer-diagnostics-market-
supplier-shares-and-sales-forecasts-for-40-tumor-markers-by-market-segment.html
Major points covered in Table of Contents of this report include
Introduction


Worldwide Market and Technology Overview


A. Cancer Statistics and Etiology
1. Brest Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer


B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
- ADA
- B-Protein
- PNP
- 5'-Nucleotidase
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opiod Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen


C. Instrumentation Review And Market Needs
1. Abbott AxSYM
2. Abbott Architect c4000
3. Abbott Architect i2000 Series
4. Abbott Architect ci8200 System
5. Beckman Coulter UniCel Series
6. Beckman Coulter Access
7. Binding Site ESP600
8. bioMerieux Mini Vidas
9. Carolina Chemistries BioLis 24i
10. DiaSorin Liaison
11. Horiba ABX Pentra 400
12. Inverness DS2
13. J&J Vitros ECi/ECiQ
14. J&J Vitros 3600
15. J&J Vitros 5600
16. Olympus AU5400
17. Olympus AU3000i
18. Olympus AU2700
19. Roche Modular Analytics
20. Roche Cobas Integra 400
21. Roche Cobas Integra 400 Plus
22. Roche Elecsys
23. Roche Cobas c311
24. Siemens ADVIA Centaur
25. Siemens Dimension
26. Siemens Dimension RxL Max
27. Siemens Dimension Vista 500
28. Siemens Immulite
29. Siemens Stratus
30. Tosoh AIA-Series
31. Vital Diagnostics ATAC 8000
32. Vital Diagnostics Envoy 500


D. Current and Emerging Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
- Overview
- ELISA
- Immunofiltration
- Particle-Membrane Capture Immunoassay
- Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
- Chemiluminescence
- Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
H. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
3. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
- PCR
- DAP-PCR
- Immuno-PCR
- QC-PCR
- CAR
- DNA
- HPA
- LCR
- NASBA
- QBR
- SDA
- 3 SR, and others
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
E. Personal Testing
Japan
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth and Major Suppliers
Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
Design Criteria for Decentralized Testing Products
Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
Competitive Profiles
- Abbott
- AdnaGen
- Applied Gene Technologies
- Arca
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- Cepheid
- Correlogic Systems
- Dako
- Decode
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Gen-Probe
- Guided Therapeutics
- Hologic
- Ipsogen
- Kreatech
- Kyowa Medex
- Life Technologies
- Mackay Life Sciences
- Myriad Genetics
- Nanogen Elitech
- OncoLab
- Otho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila


Appendixes
Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technology
and Applications
Appendix II: Assumed Currency Exchange Rates


List of Tables
Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests
List of Tables (continued)
Major Companies Developing or Marketing
HCG Tests
Major Companies Developing or Marketing
Insulin Tests
Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications
In Cancer Diagnosis
List of Tables (continued)
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis
Executive Summary Table: Japan, Total Tumor
Marker Test Volume and Sales Forecast by
Market Segment
Japan, Estimated Cancer Death Rates
Per 100,000 Population
Japan, Laboratories Performing Tumor
Marker Tests by Market Segment
Japan, Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
Commercial/Private Laboratories
Performing Tumor Marker Tests
By Annual Test Volume
Japan, Total Tumor Marker Testing Volume
Forecast by Market Segment
Japan, All Market Segments Major Tumor
Marker Test Volume Forecast
Japan, Hospital Laboratories Major Tumor
Marker Test Volume Forecast by Test
Japan, Commercial/Private Laboratories Major
Tumor Marker Test Volume Forecast
Japan, Total Tumor Marker Sales
Forecast by Market Segment
Japan, All Market Segments Major Tumor
Marker Sales Forecast by Test
Japan, Hospital Laboratories Major Tumor
Marker Sales Forecast by Test
List of Tables (continued)
Japan, Commercial/Private Laboratories Major
Tumor Marker Sales Forecast by Test
Japan, ACTH Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, AFP Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, Beta-2 Microglobulin Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, CA 15-3/27.29 Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Calcitonin Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Cathepsin Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, CEA Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Chromogranin Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, Colon-Specific Antigen Test Volume
And Diagnostics Sales Forecast by Market
Segment
List of Tables (continued)
Japan, Cytokeratins Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, Estrogen Receptor Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, Ferritin Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, Gastrin Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, HCG Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Interferons Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, Interleukins Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, Lymphocyte Subtyping Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, NSE Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, Nucleolar Test Volume and
Diagnostics Sales Forecast by Market
Segment
List of Tables (continued)
Japan, Occult Blood Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, Oncogenes Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, Pancreatic Oncofetal Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, PAP Smear Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, Parathyroid Hormone
Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Progesterone Receptor
Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, PAP Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, PSA Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, S-100 Protein Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, Serotonin Test Volume and
Diagnostics Sales Forecast by Market
Segment
List of Tables (continued)
Japan, Sialic Acid Test Volume and
Diagnostics Sales Forecast by Market
Segment
Japan, Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, TDT Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Thymidine Kinase
Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Thyroglobulin
Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, TPA, Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, Total Tumor Marker
Sales by Major Suppliers
Japan, AFP Testing Market Diagnostics
Sales by Major Supplier
Japan, CA 15-3/27.29 Testing Market
Diagnostics Sales by Major Supplier
Japan, CA 19-9 Testing Market Diagnostics
Sales by Major Supplier
Japan, CA 125 Testing Market Diagnostics
Sales by Major Supplier
Japan, Calcitonin Testing Market Diagnostics
Sales by Major Supplier
List of Tables (continued)
Japan, PAP Testing Market Diagnostics
Sales by Major Supplier
Japan, PSA Testing Market Diagnostics
Sales by Major Supplier


Contact: sales@reportsandreports.com for more information.

Más contenido relacionado

La actualidad más candente

Forsythe protocol 2014 summit
Forsythe protocol 2014 summitForsythe protocol 2014 summit
Forsythe protocol 2014 summitTahoe eLab
 
1805 bio equity_podium v3
1805 bio equity_podium v31805 bio equity_podium v3
1805 bio equity_podium v3targovax2017
 
PharmaMar-corporate-presentation
PharmaMar-corporate-presentationPharmaMar-corporate-presentation
PharmaMar-corporate-presentationVincenzo Esposito
 
Seattle Genetics Fact Sheet June 2016
Seattle Genetics Fact Sheet June 2016Seattle Genetics Fact Sheet June 2016
Seattle Genetics Fact Sheet June 2016Louis Bock
 
Global malignant melanoma drug market & clinical pipeline insight
Global malignant melanoma drug market & clinical pipeline insightGlobal malignant melanoma drug market & clinical pipeline insight
Global malignant melanoma drug market & clinical pipeline insightRajesh Sarma
 
5th annual peptides congress 2018
5th annual peptides congress 20185th annual peptides congress 2018
5th annual peptides congress 2018targovax2017
 
180606 trvx jef podium final_web
180606 trvx jef podium final_web180606 trvx jef podium final_web
180606 trvx jef podium final_webtargovax2017
 
180504 1 q18 presentation_v7
180504 1 q18 presentation_v7180504 1 q18 presentation_v7
180504 1 q18 presentation_v7targovax2017
 
1804 china bio_podium
1804 china bio_podium1804 china bio_podium
1804 china bio_podiumtargovax2017
 
The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017
The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017
The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017Tahoe eLab
 
Download Global t cell lymphoma market & clinical pipeline insight
Download Global t cell lymphoma market & clinical pipeline insightDownload Global t cell lymphoma market & clinical pipeline insight
Download Global t cell lymphoma market & clinical pipeline insightKuicK Research
 
1802 4 q17-presentation-v6_final_for-web
1802 4 q17-presentation-v6_final_for-web1802 4 q17-presentation-v6_final_for-web
1802 4 q17-presentation-v6_final_for-webtargovax2017
 
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17Tahoe eLab
 
180611 company update
180611 company update180611 company update
180611 company updatetargovax2017
 
2013 Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities a...
2013 Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities a...2013 Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities a...
2013 Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities a...ReportsnReports
 
Global cancer stem cell therapy market outlook 2020
Global cancer stem cell therapy market outlook 2020Global cancer stem cell therapy market outlook 2020
Global cancer stem cell therapy market outlook 2020KuicK Research
 

La actualidad más candente (20)

Forsythe protocol 2014 summit
Forsythe protocol 2014 summitForsythe protocol 2014 summit
Forsythe protocol 2014 summit
 
1805 bio equity_podium v3
1805 bio equity_podium v31805 bio equity_podium v3
1805 bio equity_podium v3
 
Cancer Dx Algorithm
Cancer Dx AlgorithmCancer Dx Algorithm
Cancer Dx Algorithm
 
PharmaMar-corporate-presentation
PharmaMar-corporate-presentationPharmaMar-corporate-presentation
PharmaMar-corporate-presentation
 
Seattle Genetics Fact Sheet June 2016
Seattle Genetics Fact Sheet June 2016Seattle Genetics Fact Sheet June 2016
Seattle Genetics Fact Sheet June 2016
 
Global malignant melanoma drug market & clinical pipeline insight
Global malignant melanoma drug market & clinical pipeline insightGlobal malignant melanoma drug market & clinical pipeline insight
Global malignant melanoma drug market & clinical pipeline insight
 
5th annual peptides congress 2018
5th annual peptides congress 20185th annual peptides congress 2018
5th annual peptides congress 2018
 
Advances and Challenges in Refining the Use of Cancer Immunotherapies Through...
Advances and Challenges in Refining the Use of Cancer Immunotherapies Through...Advances and Challenges in Refining the Use of Cancer Immunotherapies Through...
Advances and Challenges in Refining the Use of Cancer Immunotherapies Through...
 
180606 trvx jef podium final_web
180606 trvx jef podium final_web180606 trvx jef podium final_web
180606 trvx jef podium final_web
 
180504 1 q18 presentation_v7
180504 1 q18 presentation_v7180504 1 q18 presentation_v7
180504 1 q18 presentation_v7
 
1804 china bio_podium
1804 china bio_podium1804 china bio_podium
1804 china bio_podium
 
The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017
The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017
The Immune Protocol™ & The Lite LDIPT Protocol ™ 2017
 
Breast Cancer News
Breast Cancer NewsBreast Cancer News
Breast Cancer News
 
Download Global t cell lymphoma market & clinical pipeline insight
Download Global t cell lymphoma market & clinical pipeline insightDownload Global t cell lymphoma market & clinical pipeline insight
Download Global t cell lymphoma market & clinical pipeline insight
 
1802 4 q17-presentation-v6_final_for-web
1802 4 q17-presentation-v6_final_for-web1802 4 q17-presentation-v6_final_for-web
1802 4 q17-presentation-v6_final_for-web
 
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17
Dr. Forsythe The Immune Protocol™ & The Lite LDIPT Protocol ™ updated 2/2/17
 
1806 abg v6
1806 abg v61806 abg v6
1806 abg v6
 
180611 company update
180611 company update180611 company update
180611 company update
 
2013 Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities a...
2013 Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities a...2013 Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities a...
2013 Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities a...
 
Global cancer stem cell therapy market outlook 2020
Global cancer stem cell therapy market outlook 2020Global cancer stem cell therapy market outlook 2020
Global cancer stem cell therapy market outlook 2020
 

Destacado

Prevencion y tratamiento
Prevencion  y tratamientoPrevencion  y tratamiento
Prevencion y tratamientopatytobonito
 
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
Prevention and Treatment of Prostate Cancer: Technologies and Global MarketsPrevention and Treatment of Prostate Cancer: Technologies and Global Markets
Prevention and Treatment of Prostate Cancer: Technologies and Global MarketsReportsnReports
 
UCSF CER - Population Based Networks for Comparative Effectiveness Research (...
UCSF CER - Population Based Networks for Comparative Effectiveness Research (...UCSF CER - Population Based Networks for Comparative Effectiveness Research (...
UCSF CER - Population Based Networks for Comparative Effectiveness Research (...CTSI at UCSF
 
NetworkSecurity.ppt
NetworkSecurity.pptNetworkSecurity.ppt
NetworkSecurity.pptDreamMalar
 
UCSF Informatics Day 2014 - Dana Ludwig, "Research Data Browser"
UCSF Informatics Day 2014 - Dana Ludwig, "Research Data Browser"UCSF Informatics Day 2014 - Dana Ludwig, "Research Data Browser"
UCSF Informatics Day 2014 - Dana Ludwig, "Research Data Browser"CTSI at UCSF
 
Case analysis on Carriage by Air
Case analysis on Carriage by AirCase analysis on Carriage by Air
Case analysis on Carriage by AirAbhinandan Ray
 
Use Cases and Requirements for Isolated EUTRAN Operation
Use Cases and Requirements for Isolated EUTRAN OperationUse Cases and Requirements for Isolated EUTRAN Operation
Use Cases and Requirements for Isolated EUTRAN OperationYi-Hsueh Tsai
 
100519 4. nuernberger socialbar c_lorente_eigene webseite_worauf muss ich ach...
100519 4. nuernberger socialbar c_lorente_eigene webseite_worauf muss ich ach...100519 4. nuernberger socialbar c_lorente_eigene webseite_worauf muss ich ach...
100519 4. nuernberger socialbar c_lorente_eigene webseite_worauf muss ich ach...Bluepingu e.V.
 
A Holiday Retail in Review: Performance Lessons for 2014
A Holiday Retail in Review: Performance Lessons for 2014A Holiday Retail in Review: Performance Lessons for 2014
A Holiday Retail in Review: Performance Lessons for 2014Keynote Mobile Testing
 

Destacado (15)

Prevencion y tratamiento
Prevencion  y tratamientoPrevencion  y tratamiento
Prevencion y tratamiento
 
hdsf
hdsfhdsf
hdsf
 
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
Prevention and Treatment of Prostate Cancer: Technologies and Global MarketsPrevention and Treatment of Prostate Cancer: Technologies and Global Markets
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
 
Trapped by MTBF
Trapped by MTBFTrapped by MTBF
Trapped by MTBF
 
UCSF CER - Population Based Networks for Comparative Effectiveness Research (...
UCSF CER - Population Based Networks for Comparative Effectiveness Research (...UCSF CER - Population Based Networks for Comparative Effectiveness Research (...
UCSF CER - Population Based Networks for Comparative Effectiveness Research (...
 
NetworkSecurity.ppt
NetworkSecurity.pptNetworkSecurity.ppt
NetworkSecurity.ppt
 
UCSF Informatics Day 2014 - Dana Ludwig, "Research Data Browser"
UCSF Informatics Day 2014 - Dana Ludwig, "Research Data Browser"UCSF Informatics Day 2014 - Dana Ludwig, "Research Data Browser"
UCSF Informatics Day 2014 - Dana Ludwig, "Research Data Browser"
 
Carnival advisory 2013
Carnival advisory 2013Carnival advisory 2013
Carnival advisory 2013
 
Valores
ValoresValores
Valores
 
Case analysis on Carriage by Air
Case analysis on Carriage by AirCase analysis on Carriage by Air
Case analysis on Carriage by Air
 
Use Cases and Requirements for Isolated EUTRAN Operation
Use Cases and Requirements for Isolated EUTRAN OperationUse Cases and Requirements for Isolated EUTRAN Operation
Use Cases and Requirements for Isolated EUTRAN Operation
 
13 excel avancado
13 excel avancado13 excel avancado
13 excel avancado
 
100519 4. nuernberger socialbar c_lorente_eigene webseite_worauf muss ich ach...
100519 4. nuernberger socialbar c_lorente_eigene webseite_worauf muss ich ach...100519 4. nuernberger socialbar c_lorente_eigene webseite_worauf muss ich ach...
100519 4. nuernberger socialbar c_lorente_eigene webseite_worauf muss ich ach...
 
A Holiday Retail in Review: Performance Lessons for 2014
A Holiday Retail in Review: Performance Lessons for 2014A Holiday Retail in Review: Performance Lessons for 2014
A Holiday Retail in Review: Performance Lessons for 2014
 
Gemeindebrief Dez 2014/ Jan 2015
Gemeindebrief Dez 2014/ Jan 2015Gemeindebrief Dez 2014/ Jan 2015
Gemeindebrief Dez 2014/ Jan 2015
 

Similar a Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares and Sales Forecasts for 40 Tumor Markers by Market Segment

Future Horizons in the European Cancer Diagnostics Market - France, Germany, ...
Future Horizons in the European Cancer Diagnostics Market - France, Germany, ...Future Horizons in the European Cancer Diagnostics Market - France, Germany, ...
Future Horizons in the European Cancer Diagnostics Market - France, Germany, ...ReportsnReports
 
Innovative Molecular Diagnostic Technologies and Emerging Markets
Innovative Molecular Diagnostic Technologies and Emerging MarketsInnovative Molecular Diagnostic Technologies and Emerging Markets
Innovative Molecular Diagnostic Technologies and Emerging MarketsReportsnReports
 
2013 US Clinical Chemistry and Immunodiagnostics Markets
2013 US Clinical Chemistry and Immunodiagnostics Markets2013 US Clinical Chemistry and Immunodiagnostics Markets
2013 US Clinical Chemistry and Immunodiagnostics MarketsReportsnReports
 
Spain Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
Spain Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...Spain Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
Spain Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...ReportsnReports
 
Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...
Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...
Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...ReportsnReports
 
UK Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...
UK Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...UK Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...
UK Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...ReportsnReports
 
Japan Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
Japan Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...Japan Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
Japan Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...ReportsnReports
 
France Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...
France Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...France Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...
France Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...ReportsnReports
 
Italy Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
Italy Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...Italy Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
Italy Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...ReportsnReports
 
Germany Molecular Diagnostics Market: Innovative Technologies and Emerging Bu...
Germany Molecular Diagnostics Market: Innovative Technologies and Emerging Bu...Germany Molecular Diagnostics Market: Innovative Technologies and Emerging Bu...
Germany Molecular Diagnostics Market: Innovative Technologies and Emerging Bu...ReportsnReports
 
US Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...
US Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...US Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...
US Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...ReportsnReports
 
Targeted genomic sequencing assay for comprehensive molecular characterizatio...
Targeted genomic sequencing assay for comprehensive molecular characterizatio...Targeted genomic sequencing assay for comprehensive molecular characterizatio...
Targeted genomic sequencing assay for comprehensive molecular characterizatio...Saba Anwer, MPH, MBA
 
The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...
The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...
The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...ReportLinker.com
 
2014 11-27 ODDP 2014 course, Amsterdam, Alain van Gool
2014 11-27 ODDP 2014 course, Amsterdam, Alain van Gool2014 11-27 ODDP 2014 course, Amsterdam, Alain van Gool
2014 11-27 ODDP 2014 course, Amsterdam, Alain van GoolAlain van Gool
 
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLERBiocat, BioRegion of Catalonia
 
The Forsythe Immune Protocol, outcome based Investigation
The Forsythe Immune Protocol, outcome based InvestigationThe Forsythe Immune Protocol, outcome based Investigation
The Forsythe Immune Protocol, outcome based InvestigationTahoe eLab
 
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Fundación Ramón Areces
 
Diagnostic Testing in Ancillary Hospital Locations: Innovative Technologies a...
Diagnostic Testing in Ancillary Hospital Locations: Innovative Technologies a...Diagnostic Testing in Ancillary Hospital Locations: Innovative Technologies a...
Diagnostic Testing in Ancillary Hospital Locations: Innovative Technologies a...ReportsnReports
 

Similar a Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares and Sales Forecasts for 40 Tumor Markers by Market Segment (20)

Future Horizons in the European Cancer Diagnostics Market - France, Germany, ...
Future Horizons in the European Cancer Diagnostics Market - France, Germany, ...Future Horizons in the European Cancer Diagnostics Market - France, Germany, ...
Future Horizons in the European Cancer Diagnostics Market - France, Germany, ...
 
Innovative Molecular Diagnostic Technologies and Emerging Markets
Innovative Molecular Diagnostic Technologies and Emerging MarketsInnovative Molecular Diagnostic Technologies and Emerging Markets
Innovative Molecular Diagnostic Technologies and Emerging Markets
 
2013 US Clinical Chemistry and Immunodiagnostics Markets
2013 US Clinical Chemistry and Immunodiagnostics Markets2013 US Clinical Chemistry and Immunodiagnostics Markets
2013 US Clinical Chemistry and Immunodiagnostics Markets
 
Spain Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
Spain Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...Spain Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
Spain Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
 
Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...
Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...
Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...
 
UK Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...
UK Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...UK Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...
UK Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...
 
Japan Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
Japan Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...Japan Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
Japan Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
 
France Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...
France Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...France Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...
France Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...
 
Italy Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
Italy Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...Italy Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
Italy Molecular Diagnostics Market: Innovative Technologies and Emerging Busi...
 
Germany Molecular Diagnostics Market: Innovative Technologies and Emerging Bu...
Germany Molecular Diagnostics Market: Innovative Technologies and Emerging Bu...Germany Molecular Diagnostics Market: Innovative Technologies and Emerging Bu...
Germany Molecular Diagnostics Market: Innovative Technologies and Emerging Bu...
 
US Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...
US Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...US Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...
US Molecular Diagnostics Market: Innovative Technologies and Emerging Busines...
 
Targeted genomic sequencing assay for comprehensive molecular characterizatio...
Targeted genomic sequencing assay for comprehensive molecular characterizatio...Targeted genomic sequencing assay for comprehensive molecular characterizatio...
Targeted genomic sequencing assay for comprehensive molecular characterizatio...
 
The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...
The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...
The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...
 
2014 11-27 ODDP 2014 course, Amsterdam, Alain van Gool
2014 11-27 ODDP 2014 course, Amsterdam, Alain van Gool2014 11-27 ODDP 2014 course, Amsterdam, Alain van Gool
2014 11-27 ODDP 2014 course, Amsterdam, Alain van Gool
 
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
"Breaking up pharma´s value chain - what can we expect", MICHAEL MÜLLER
 
The Forsythe Immune Protocol, outcome based Investigation
The Forsythe Immune Protocol, outcome based InvestigationThe Forsythe Immune Protocol, outcome based Investigation
The Forsythe Immune Protocol, outcome based Investigation
 
NeoGenomics Company Overview Presentation 2014-09-12
NeoGenomics Company Overview Presentation 2014-09-12NeoGenomics Company Overview Presentation 2014-09-12
NeoGenomics Company Overview Presentation 2014-09-12
 
Tocc ancer currentnemergingcancerdiag
Tocc ancer currentnemergingcancerdiagTocc ancer currentnemergingcancerdiag
Tocc ancer currentnemergingcancerdiag
 
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. José Baselga - Simposio Internacional 'Terapias oncológicas avanzadas'
 
Diagnostic Testing in Ancillary Hospital Locations: Innovative Technologies a...
Diagnostic Testing in Ancillary Hospital Locations: Innovative Technologies a...Diagnostic Testing in Ancillary Hospital Locations: Innovative Technologies a...
Diagnostic Testing in Ancillary Hospital Locations: Innovative Technologies a...
 

Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares and Sales Forecasts for 40 Tumor Markers by Market Segment

  • 1. Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares and Sales Forecasts for 40 Tumor Markers by Market Segment Report Details: Published:August 2012 No. of Pages: 590 Price: Single User License – US$6700 Highlights •Comprehensive 590-page analysis of the Japanese tumor marker testing market. •Major issues pertaining to the Japanese laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. •Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. •Ten-year test volume and sales forecasts over for 40 tumor marker performed in Japanese hospitals, commercial laboratories and physician offices. •Placements and installed base of automated and semi-automated analyzers used for tumor marker testing. •Current instrumentation technologies and feature comparison of leading analyzers. •Sales and market shares of leading suppliers. •Emerging diagnostic technologies and their potential market applications. •Product development opportunities. •Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. •Business opportunities and strategic recommendations for suppliers. Contains: 590 pages and 95 tables. Get your copy of this report @ http://www.reportsnreports.com/reports/187741-future-horizons-in-the-japanese-cancer-diagnostics-market- supplier-shares-and-sales-forecasts-for-40-tumor-markers-by-market-segment.html
  • 2. Major points covered in Table of Contents of this report include Introduction Worldwide Market and Technology Overview A. Cancer Statistics and Etiology 1. Brest Cancer 2. Lung Cancer 3. Colon and Rectum Cancer 4. Prostate Cancer 5. Stomach Cancer 6. Leukemia 7. Lymphoma 8. Oral Cancer 9. Skin Cancer 10. Uterine Cancer 11. Ovarian Cancer 12. Bladder Cancer B. Major Current And Emerging Cancer Diagnostic Tests 1. Introduction 2. Tumor Marker Classification 3. ACTH 4. Alpha-Fetoprotein (AFP) 5. Beta-2 Microglobulin 6. CA 15-3/27.29 7. CA 19-9 8. CA-125 9. Calcitonin 10. Carcinoembrionic Antigen (CEA) 11. Estrogen and Progesterone Receptors 12. Ferritin 13. Gastrin 14. Human Chorionic Gonadotropin (HCG) 15. Insulin 16. NSE 17. Occult Blood 18. PAP Smear/HPV 19. Prostatic Acid Phosphatase (PAP) 20. Prostate-Specific Antigen (PSA) 21. Squamous Cell Carcinoma Antigen (SCC) 22. T and B Lymphocytes
  • 3. 23. TdT 24. Thyroglobulin 25. Tissue Polypeptide Antigen (TPA) 26. Biochemical Tumor Markers - ADA - B-Protein - PNP - 5'-Nucleotidase 27. Oncogenes - Abl/abl-bcr - AIB1 - BCL-2 - BRCA1 - CD44 - C-fos - C-myb - C-myc - CYP-17 - Erb-B - HPC1 - N-myc - P40 - P51 - P53 - PIK3CA - PTI-1 - Ras - Reg - Sis - Src 28. Polypeptide Growth Factors - Basic Fibroblast Growth Factor - Beta-TGF - Cachectin (TNT) - Calmodulin - ECFR - Nerve Growth Factor (NGF) - Epidermal Growth Factor (EGF) - Ornithine Decarboxylase - Transferrin - Transforming Growth Factor-Alpha 29. Ectopic Hormones
  • 4. 30. Colony Stimulating Factors 31. Lymphokines - Alpha-Interferon - B Cell Growth Factors - B Cell Growth Factor (BCGF) - Gamma-Interferon - Interleukin-1 (IL-1) - Macrophage Activating Factor 32. Immunohistochemical Stains 33. Emerging Tumor Markers - N-Acetylglucosamine - Actin - Alpha-Actin - Antineuronal Antibodies - 7B2 - B72.3 - Bax - BCD-F9 - BLCA-4 - Blood Group Antigens A,B,H - CA 50 - CA 72-4/TAG-72 - CA 195 - CA-242 - CA-549 - CAM 26 - CAR-3 - Cathepsin-D - Chromogranin A and B - Cluster 1 Antigen - Cluster-5/5A Antigen - CTA - CU18 - DR-70 - DU-PAN-2 - Endometrial Bleeding Associated Factor - Endostatin - Epithelial Membrane Antigen - Feulgen Hydrolysis - Fibronectin - FSH - (1->3)-L-fucosyltransferase
  • 5. - Gastrin-Releasing Peptide (GRP) - GDCFP-15 - Glucagon - Glycoamines - H23 - Her-2 - Human Carcinoma Antigen - HPA - HSP27 - Intermediate Filaments - Cytokeratins/CK18/Cyfra 21-1 - Desmin - Gliofibrillary Acid Protein - Neurofilaments - Vimentin - KA 93 - Kinases - KP16D3 - LAI - Leukocyte Common Antigen - Lewis Antigens - Lysophosphatidic Acid (LPA) - Ma 695/Ma 552 - MABDF3 - MAG - ME1 - Minactivin - MN/CA9 - MSA - Mucin Cancer Antigen (MCA) - Multiple Tumor Suppressor 1 - Myosin - NEA-130 - NMP22 - OA-519 - Opiod Peptides - P-glycoprotein - Pancreatic Oncofetal Antigen (POA) - Placental Lactogen - PR92 - Proliferative Index, Ki-67 - Px
  • 6. - RB Inactivation/Deletion - Ret - SCCL 175 - Selectin - Sialic Acid - Sialyl SSEA-1/SLX - SN10 - Somatostatin - TA-90 - TABA - Tachykinin - TAG 12 - TPS - Troponin - Tubulin - VCAM - VEGF - Villen C. Instrumentation Review And Market Needs 1. Abbott AxSYM 2. Abbott Architect c4000 3. Abbott Architect i2000 Series 4. Abbott Architect ci8200 System 5. Beckman Coulter UniCel Series 6. Beckman Coulter Access 7. Binding Site ESP600 8. bioMerieux Mini Vidas 9. Carolina Chemistries BioLis 24i 10. DiaSorin Liaison 11. Horiba ABX Pentra 400 12. Inverness DS2 13. J&J Vitros ECi/ECiQ 14. J&J Vitros 3600 15. J&J Vitros 5600 16. Olympus AU5400 17. Olympus AU3000i 18. Olympus AU2700 19. Roche Modular Analytics 20. Roche Cobas Integra 400 21. Roche Cobas Integra 400 Plus 22. Roche Elecsys
  • 7. 23. Roche Cobas c311 24. Siemens ADVIA Centaur 25. Siemens Dimension 26. Siemens Dimension RxL Max 27. Siemens Dimension Vista 500 28. Siemens Immulite 29. Siemens Stratus 30. Tosoh AIA-Series 31. Vital Diagnostics ATAC 8000 32. Vital Diagnostics Envoy 500 D. Current and Emerging Technologies 1. Monoclonal and Polyclonal Antibodies 2. Immunoassays a. Technological Principle b. Radioimmunoassay (RIA) c. Enzyme Immunoassays (EIA) - Overview - ELISA - Immunofiltration - Particle-Membrane Capture Immunoassay - Enzyme Amplification d. Fluorescent Immunoassays e. Luminescence - Chemiluminescence - Bioluminescence f. Latex Agglutination g. Immunoprecipitation H. Affinity Chromatographu e. Liposome Flow-Injection Immunoassay 3. Molecular Diagnostics a. Technology Overview b. Amplification Methods - PCR - DAP-PCR - Immuno-PCR - QC-PCR - CAR - DNA - HPA - LCR - NASBA
  • 8. - QBR - SDA - 3 SR, and others 4. Chromosome Analysis a. Chronic Myelogenous Leukemia (CML) b. Acute Myeloid Leukemia (AML) c. Acute Lymphoblastic Leukemia (ALL) d. Malignant Lymphomas Lymphoid Malignancies e. Chronic Lymphocytic Leukemia (CLL) f. Solid Cancers g. Chromosomal Translocation and Oncogenes 5. Artificial Intelligence 6. Flow Cytometry 7. Two Dimensional Gel Electrophoresis (2-DGE) 8. Biosensors 9. Competing/Complementing Technologies a. CT b. MRI c. NMR d. PET e. Photonics Spectroscopy E. Personal Testing Japan A. Executive Summary B. Business Environment C. Market Structure D. Market Size, Growth and Major Suppliers Major Product Development Opportunities A. Reagent Kits and Test Systems/Panels B. Instrumentation C. Computers, Software and Automation D. Auxiliary Products Design Criteria for Decentralized Testing Products Alternative Market Penetration Strategies A. Internal Development B. Collaborative Arrangements C. University Contracts D. Distribution Strategies 1. Marketing Approaches 2. Product Complexity 3. Customer Preference 4. Established Suppliers
  • 9. 5. Emerging Suppliers 6. Major Types of Distributors 7. Market Segmentation Factor Potential Market Entry Barriers and Risks A. Market Maturity B. Cost Containment C. Competition D. Technological Edge and Limitations E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges Competitive Profiles - Abbott - AdnaGen - Applied Gene Technologies - Arca - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - Cepheid - Correlogic Systems - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Ipsogen - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences
  • 10. - Myriad Genetics - Nanogen Elitech - OncoLab - Otho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila Appendixes Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications Appendix II: Assumed Currency Exchange Rates List of Tables Tumor Marker Classification Major Companies Developing or Marketing ACTH Tests Major Companies Developing or Marketing AFP Tests Major Companies Developing or Marketing Beta-2 Microglobulin Tests Major Companies Developing or Marketing CA 15-3/27.29 Tests Major Companies Developing or Marketing CA 19-9 Tests Major Companies Developing or Marketing CA 125 Tests Major Companies Developing or Marketing
  • 11. Calcitonin Tests Major Companies Developing or Marketing CEA Tests Major Companies Developing or Marketing Estrogen Receptor Tests Major Companies Developing or Marketing Progesterone Receptor Tests Major Companies Developing or Marketing Ferritin Tests Major Companies Developing or Marketing Gastrin Tests List of Tables (continued) Major Companies Developing or Marketing HCG Tests Major Companies Developing or Marketing Insulin Tests Major Companies Developing or Marketing NSE Tests Major Companies Developing or Marketing Occult Blood Tests Major Companies Developing or Marketing PAP Smear/HPV Tests Major Companies Developing or Marketing PAP Tests Major Companies Developing or Marketing PSA Tests Major Companies Developing or Marketing Lymphocyte Subclassification Tests Biochemical Markers Potential Applications In Cancer Diagnosis Oncogenes Potential Applications In Cancer Diagnosis Major Companies Developing or Marketing Oncogene Tests Growth Factors Potential Applications In Cancer Diagnosis Colony Stimulating Factors Potential Applications in Cancer Diagnosis Lymphokines Potential Applications In Cancer Diagnosis List of Tables (continued) Immunohistochemical Stains Potential
  • 12. Applications in Cancer Diagnosis Executive Summary Table: Japan, Total Tumor Marker Test Volume and Sales Forecast by Market Segment Japan, Estimated Cancer Death Rates Per 100,000 Population Japan, Laboratories Performing Tumor Marker Tests by Market Segment Japan, Hospital Laboratories Performing Tumor Marker Tests by Bed Size Commercial/Private Laboratories Performing Tumor Marker Tests By Annual Test Volume Japan, Total Tumor Marker Testing Volume Forecast by Market Segment Japan, All Market Segments Major Tumor Marker Test Volume Forecast Japan, Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test Japan, Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast Japan, Total Tumor Marker Sales Forecast by Market Segment Japan, All Market Segments Major Tumor Marker Sales Forecast by Test Japan, Hospital Laboratories Major Tumor Marker Sales Forecast by Test List of Tables (continued) Japan, Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test Japan, ACTH Test Volume and Diagnostics Sales Forecast by Market Segment Japan, AFP Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment Japan, CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
  • 13. Japan, CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, CEA Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Colon-Specific Antigen Test Volume And Diagnostics Sales Forecast by Market Segment List of Tables (continued) Japan, Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, HCG Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Interferons Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment Japan, NSE Test Volume and Diagnostics Sales Forecast by Market Segment
  • 14. Japan, Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment List of Tables (continued) Japan, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment Japan, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment Japan, PAP Test Volume and Diagnostics Sales Forecast by Market Segment Japan, PSA Test Volume and Diagnostics Sales Forecast by Market Segment Japan, S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment List of Tables (continued) Japan, Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment Japan, TDT Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Thymidine Kinase
  • 15. Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, TPA, Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Total Tumor Marker Sales by Major Suppliers Japan, AFP Testing Market Diagnostics Sales by Major Supplier Japan, CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier Japan, CA 19-9 Testing Market Diagnostics Sales by Major Supplier Japan, CA 125 Testing Market Diagnostics Sales by Major Supplier Japan, Calcitonin Testing Market Diagnostics Sales by Major Supplier List of Tables (continued) Japan, PAP Testing Market Diagnostics Sales by Major Supplier Japan, PSA Testing Market Diagnostics Sales by Major Supplier Contact: sales@reportsandreports.com for more information.